Any current/future new fundraising through debt or equity?

No current plans for additional capex beyond the INR120-125 crores pharma expansion. No mention of new debt or equity fundraising discussed in the call. Existing expansions are being funded with disciplined capital use; debt to equity stands at 0.47x, long-term debt to equity at 0.16x. Capacity expansions or investments will only be triggered once utilization consistently exceeds 75-80%. Focus remains on sweating existing assets and improving utilization before any further major capital investments. No indications of fresh fundraising through debt or equity were provided in the transcript.

Any current/future capex/capital investment/strategic investment?

Pharma division capex of about INR120-125 crores is underway, expected to be completed between Q1 and Q2 of the current year, with commercial production starting by Q2. Expansion involves setting up a modular plant with a total of 36 molding machines; currently installing 12 machines. No other major capex plans beyond the pharma division at present. Future capacity expansions will only be triggered when utilization consistently exceeds 75-80%. Marginal investments may be made on specialized equipment or tooling based on specific business needs, especially for in-house products. Existing equipm

Future growth expectations in sales/revenue/volumes?

Pharma division expected to grow 45%-50% in FY '24; targeting around 14-15 million pens from 10 million in FY '23. Pharma growth to maintain at least 30% annually for the next 4 years (Amit Sanghvi). Auto injector segment anticipated to contribute growing revenue by FY '25; higher value products than pens. Steel division to see good growth and improved utilization in FY '24 compared to previous year. Toys business expected to decline or remain lower in FY '24 due to competitive pricing and market conditions. Capacity expansions triggered only after reaching 75%-80% utilization; curre

Future growth expectations in earnings/operating earnings/profits/EPS?

The company refrains from giving explicit guidance on long-term ROCE, earnings, returns, or profits. (Page 15) Pharma division is expected to maintain upwards of 30% growth over the next 4 years, but exact forecasting is difficult due to its developing nature. (Page 8) The focus remains on sustaining and expanding margins as pharma business scales up with a strong pipeline. (Page 5) The company anticipates improvements in capacity utilization, especially in the steel business by FY '25. (Page 9) Growth and margin expansion are expected as pharma scales up further, though global economic challe

Current/ Expected Orderbook/ Pending Orders?

The company has a healthy order book in the steel division, with expectations for full plant utilization in due course, though no specific timeline was shared. The pharma division is actively growing, with addition of new customers and increasing commercial sales, especially in pen products; however, specific order book figures were not disclosed. Discussions with multiple players continue for new orders, but detailed customer-wise order backlog or pending orders are not shared due to confidentiality. In the toys division, the company sees no growth and expects lower sales, being selective due

Shaily Engineering Plastics LtdQ4 FY23Consumer Durables

Shaily Engineering Plastics Ltd Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3,105.2P/E: 80.3Market Cap: ₹14.3K CrSector: Consumer Durables

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Pharma division expected to grow 45%-50% in FY '24; targeting around 14-15 million pens from 10 million in FY '23.
Pharma growth to maintain at least 30% annually for the next 4 years (Amit Sanghvi).
Auto injector segment anticipated to contribute growing revenue by FY '25; higher value products than pens.
Steel division to see good growth and improved utilization in FY '24 compared to previous year.
Toys business expected to decline or remain lower in FY '24 due to competitive pricing and market conditions.
Capacity expansions triggered only after reaching 75%-80% utilization; currently increasing capacity without major capex.
Overall business growth and margin expansion expected as pharma scales up with a strong pipeline.
Some uncertainty and no explicit long-term revenue guidance given by management.

Margin guidance

Category 3

The company refrains from giving explicit guidance on long-term ROCE, earnings, returns, or profits. (Page 15)
Pharma division is expected to maintain upwards of 30% growth over the next 4 years, but exact forecasting is difficult due to its developing nature. (Page 8)
The focus remains on sustaining and expanding margins as pharma business scales up with a strong pipeline. (Page 5)
The company anticipates improvements in capacity utilization, especially in the steel business by FY '25. (Page 9)
Growth and margin expansion are expected as pharma scales up further, though global economic challenges have delayed expected growth by about a year. (Page 5)
No firm guidance on EPS or profitability growth was provided, emphasizing disciplined capital use and margin focus. (Pages 3-4, 15)

See what Shaily Engineering Plastics Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No current plans for additional capex beyond the INR120-125 crores pharma expansion.
No mention of new debt or equity fundraising discussed in the call.
Existing expansions are being funded with disciplined capital use; debt to equity stands at 0.47x, long-term debt to equity at 0.16x.
Capacity expansions or investments will only be triggered once utilization consistently exceeds 75-80%.
Focus remains on sweating existing assets and improving utilization before any further major capital investments.
No indications of fresh fundraising through debt or equity were provided in the transcript.

Order book

Yes

The company has a healthy order book in the steel division, with expectations for full plant utilization in due course, though no specific timeline was shared.
The pharma division is actively growing, with addition of new customers and increasing commercial sales, especially in pen products; however, specific order book figures were not disclosed.
Discussions with multiple players continue for new orders, but detailed customer-wise order backlog or pending orders are not shared due to confidentiality.
In the toys division, the company sees no growth and expects lower sales, being selective due to margin challenges and competition, leading to limited new orders.
Overall, the company refrains from giving specific order book or pending order numbers publicly but indicates ongoing expansion and customer engagement.

See what Shaily Engineering Plastics Ltd management said on order book — free account, 30 seconds.

Capex plans

Pharma division capex of about INR120-125 crores is underway, expected to be completed between Q1 and Q2 of the current year, with commercial production starting by Q2.
Expansion involves setting up a modular plant with a total of 36 molding machines; currently installing 12 machines.
No other major capex plans beyond the pharma division at present.
Future capacity expansions will only be triggered when utilization consistently exceeds 75-80%.
Marginal investments may be made on specialized equipment or tooling based on specific business needs, especially for in-house products.
Existing equipment in the Toy division is multipurpose and can be used for other products/businesses to improve utilization, avoiding dedicated investments.
Overall focus is on improving utilization and sweating existing assets before undertaking significant new capital expenditure.

Track Shaily Engineering Plastics Ltd — get its next earnings analysis in your feed

How does Shaily Engineering Plastics Ltd rank vs peers in Consumer Durables?

Pro feature

ThisShaily Engineering Plastics Ltd

Rev 3Mar 3

See where Shaily Engineering Plastics Ltd sits in Consumer DurablesSee which companies these are, and every other name in the sector.Open rankings

How does Shaily Engineering Plastics Ltd rank in Consumer Durables?

Compare Shaily Engineering Plastics Ltd against every Consumer Durables company (Q4 FY23) on revenue, margins and earnings-call signals.

View Consumer Durables leaderboard →

What Shaily Engineering Plastics Ltd's management said in earlier quarters

Others in Consumer Durables this season

Varmora Granito Ltd (Q2 FY27)
Revenue from operations for the quarter ended September 30, 2026: ₹3,870.64 million . Key investor presentation takeaways from Varmora Granito Ltd's Q2 FY27 inv
Parin Enterpris. (Q2 FY27)
For the quarter ended 30 September 2026, consolidated revenue from operations was ₹8,643.27 lakhs. Key results statement takeaways from Parin Enterprises Ltd's
Voltas Ltd (Q2 FY26)
Market share in cooling products category progressively growing: 16% in Q4FY25, 17.8% in Q1FY26, 18.5% in Q2FY26. Key concall takeaways from Voltas's Q2 FY26…
Nitco Ltd (Q2 FY26)
Q2 FY26 revenue from operations: INR 107.1 crores, a 64% YoY increase from INR 65.5 crores in Q2 FY25. Key investor presentation takeaways from Nitco Ltd's Q2 F

Compare:vs Titan Company vs Asian Paints vs LG Electronics

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Shaily Engineering Plastics Ltd Q4 FY23 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Shaily Engineering Plastics Ltd rank in Consumer Durables?

Continue your research

What Shaily Engineering Plastics Ltd's management said in earlier quarters

Others in Consumer Durables this season